Literature DB >> 27406390

Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Valeria Cambiaghi1, Eleonora Vitali1, Diego Morone1, Erika Peverelli2, Anna Spada2, Giovanna Mantovani2, Andrea Gerardo Lania3,4.   

Abstract

Somatostatin exerts inhibitory effects on hormone secretion and cell proliferation via five receptor subtypes (SST1-SST5), whose internalization is regulated by β-arrestins. The receptor domains involved in these effects have been only partially elucidated. The aim of the study is to characterize the molecular mechanism and determinants responsible for somatostatin receptor 2 internalization and signaling in pancreatic neuroendocrine QGP-1 cell line, focusing on the third intracellular loop and carboxyl terminal domains. We demonstrated that in cells transfected with somatostatin receptor 2 third intracellular loop mutant, no differences in β-arrestins recruitment and receptor internalization were observed after somatostatin receptor 2 activation in comparison with cells bearing wild-type somatostatin receptor 2. Conversely, the truncated somatostatin receptor 2 failed to recruit β-arrestins and to internalize after somatostatin receptor 2 agonist (BIM23120) incubation. Moreover, the inhibitory effect of BIM23120 on cell proliferation, cyclin D1 expression, P-ERK1/2 levels, apoptosis and vascular endothelial growth factor secretion was completely lost in cells transfected with either third intracellular loop or carboxyl terminal mutants. In conclusion, we demonstrated that somatostatin receptor 2 internalization requires intact carboxyl terminal while the effects of SS on cell proliferation, angiogenesis and apoptosis mediated by somatostatin receptor 2 need the integrity of both third intracellular loop and carboxyl terminal.

Entities:  

Keywords:  Somatostatin 2 receptor subtype; Somatostatin receptor; pancreatic neuroendocrine tumors; β-arrestins

Mesh:

Substances:

Year:  2016        PMID: 27406390     DOI: 10.1007/s12020-016-1026-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  57 in total

1.  Beta-arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cells.

Authors:  Sabrina Brasselet; Stéphanie Guillen; Jean-Pierre Vincent; Jean Mazella
Journal:  FEBS Lett       Date:  2002-04-10       Impact factor: 4.124

Review 2.  Molecular mechanisms of somatostatin receptor trafficking.

Authors:  Zsolt Csaba; Stéphane Peineau; Pascal Dournaud
Journal:  J Mol Endocrinol       Date:  2012-01-25       Impact factor: 5.098

Review 3.  Antitumor effects of somatostatin.

Authors:  Stéphane Pyronnet; Corinne Bousquet; Souad Najib; Rania Azar; Hanane Laklai; Christiane Susini
Journal:  Mol Cell Endocrinol       Date:  2008-02-13       Impact factor: 4.102

4.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

5.  C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest.

Authors:  K Sharma; Y C Patel; C B Srikant
Journal:  Mol Endocrinol       Date:  1999-01

6.  Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Authors:  Falko Nagel; Christian Doll; Florian Pöll; Andrea Kliewer; Helmut Schröder; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2011-02-17

7.  The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling.

Authors:  F Lopez; J P Estève; L Buscail; N Delesque; N Saint-Laurent; M Théveniau; C Nahmias; N Vaysse; C Susini
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

8.  Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor.

Authors:  R W Hipkin; Y Wang; A Schonbrunn
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

9.  Real-time imaging of leukotriene B₄ mediated cell migration and BLT1 interactions with β-arrestin.

Authors:  Venkatakrishna R Jala; Bodduluri Haribabu
Journal:  J Vis Exp       Date:  2010-12-23       Impact factor: 1.355

10.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

View more
  3 in total

Review 1.  Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.

Authors:  Samuel Adant; Girish M Shah; Jean-Mathieu Beauregard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

Review 2.  Somatostatin receptor radionuclide therapy in neuroendocrine tumors.

Authors:  Mintallah Haider; Satya Das; Taymeyah Al-Toubah; Eleonora Pelle; Ghassan El-Haddad; Jonathan Strosberg
Journal:  Endocr Relat Cancer       Date:  2021-03       Impact factor: 5.678

Review 3.  Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.

Authors:  Federico Gatto; Federica Barbieri; Marica Arvigo; Stefano Thellung; Jessica Amarù; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.